Abstract Details

Title Association of Disease Characteristics with Utilization of Behavioral Medicine in Patients with NMOSD and MOGAD

Topic Autoimmune Neurology

Presentation(s) P13 - Poster Session 13 (8:00 AM-9:00 AM)

Poster/Presentation
Number 6-016

Objective To evaluate utilization of behavioral medicine in patients with neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein-IgG-associated disorder (MOGAD).

Background The relationship between disease characteristics, utilization of behavioral medicine, and other healthcare services has not been well-characterized in patients with NMOSD/MOGAD.

Design/Methods

In this retrospective cohort study, patients with NMOSD/MOGAD confirmed by a neuroimmunology clinic with available clinical data between June 2015 and April 2022 were identified. Relevant variables were collected, including number of behavioral medicine appointments, diagnosis, number of other healthcare visits (admissions, emergency room visits, neurology appointments, outpatient physical and occupational therapy [PT/OT] visits), and number and type of relapses (brainstem, transverse myelitis, and optic neuritis). Nonparametric t-tests were performed to compare characteristics of patients who did and did not use behavioral medicine. Pearson correlations were used to explore relationships between disease characteristics and number of behavioral medicine appointments.

Results 196 patients (70.9% NMOSD [92.8% aquaporin-4 antibody positive], 29.1% MOGAD) were identified (median duration of symptoms 8.4 years, IQR [4.6, 16.4 years]). Of these, 21 patients (90.5% NMOSD, 9.5% MOGAD) attended at least one outpatient behavioral medicine appointment. These patients had more emergency room visits (median 3, IQR [1, 8]) than non-attendees (median 1, IQR [0, 2]) (p = .04). No significant difference was detected regarding number or type of relapse or utilization of other healthcare services (for all, p > .05). Brainstem flares and number of PT/OT visits correlated with number of behavioral medicine appointments (r = .72 and r = .56, respectively, p < .05).

Conclusions

Patients with NMOSD/MOGAD who received behavioral medicine services had greater emergency room utilization than those who did not. In our cohort, nearly 1 in 8 patients attended behavioral medicine appointments. Screening for mental health disorders in neurology clinics remains critical to appropriately identify and treat NMOSD/MOGAD patients with behavioral comorbidities.

Authors/Disclosures
Carol Swetlik, MD (Cleveland Clinic) PRESENTER	An immediate family member of Dr. Swetlik has received personal compensation for serving as an employee of Pfizer. Dr. Swetlik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genetech. Dr. Swetlik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen.
Devon Conway, MD	Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Conway has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Conway has received research support from Novartis. The institution of Dr. Conway has received research support from BMS.
	No disclosure on file
Amy Kunchok, MBBS (Cleveland Clinic - Mellen Centre)	Dr. Kunchok has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology:Open Access Journal .
	No disclosure on file
Amy B. Sullivan, PhD (Cleveland Clinic)	Dr. Sullivan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Sullivan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Serono. Dr. Sullivan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi.
Rachel Galioto	Rachel Galioto has nothing to disclose.
Albert Aboseif, DO	Dr. Aboseif has received research support from the Eugene & Marcia Applebaum Fellowship Grant.
Justin Abbatemarco, MD	Dr. Abbatemarco has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech . Dr. Abbatemarco has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics, Inc.. Dr. Abbatemarco has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Abbatemarco has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG therapeutics .

��ɫ��

��ɫ��